pharma · Diffuse Cutaneous Systemic Sclerosis · Myopia
Elan Pharmaceuticals
Elan Pharma International
Elan Pharma International is a pharma organization headquartered in EU. Primary therapeutic focus areas include Diffuse Cutaneous Systemic Sclerosis, Myopia, Sjögren’s Syndrome With Moderate-toSevere Symptom State, Breas
Treasury Building, Lower Grand Canal Street, Dublin 2, IE HQ
1969 Founded
792 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Treasury Building, Lower Grand Canal Street, Dublin 2, IE
- Founded
- 1969
- Employees
- 792
- Programs
- 18
- Drugs
- 26
- Patents
- 0
HZNP-HZN-825-303
Phase 2 · small molecule · Idiopathic Pulmonary Fibrosis
HZNP-HZN-825-303 for Idiopathic Pulmonary Fibrosis is a Phase 2 program (small_molecule) at Elan Pharma International with 1 ClinicalTrials.gov record(s).
Internal code HZNP-HZN-825-303
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Elan Pharma International
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Idiopathic Pulmonary Fibrosis
- Status
- active
- Trials
- 1